Left atrial appendage closure in very elderly patients in the French National Registry
- PMID: 37813560
- DOI: 10.1136/heartjnl-2023-322871
Left atrial appendage closure in very elderly patients in the French National Registry
Abstract
Objective: Left atrial appendage closure (LAAC) is recommended to decrease the stroke risk in patients with atrial fibrillation and contraindications to anticoagulation. However, age-stratified data are scarce. The aim of this study was to provide information on the safety and efficacy of LAAC, with emphasis on the oldest patients.
Methods: A nationwide, prospective, multicentre, observational registry was established by 53 French cardiology centres in 2018-2021. The composite primary endpoint included ischaemic stroke, systemic embolism, and unexplained or cardiovascular death. Separate analyses were done in the groups <80 years and ≥80 years.
Results: Among the 1053 patients included, median age was 79.7 (73.6-84.3) years; 512 patients (48.6%) were aged ≥80 years. Procedure-related serious adverse events were non-significantly more common in octogenarians (7.0% vs 4.4% in patients aged <80 years, respectively; p=0.07). Despite a higher mean CHA2DS2-VASc score in octogenarians, the rate of thromboembolic events during the study was similar in both groups (3.0 vs 3.1/100 patient-years; p=0.85). By contrast, all-cause mortality was significantly higher in octogenarians (15.3 vs 10.1/100 patient-years, p<0.015), due to a higher rate of non-cardiovascular deaths (8.2 vs 4.9/100 patient-years, p=0.034). The rate of the primary endpoint was 8.1/100 patient-years overall with no statistically significant difference between age groups (9.4 and 7.0/100 patient-years; p=0.19).
Conclusion: Despite a higher mean CHA2DS2-VASc score in octogenarians, the rate of thromboembolic events after LAAC in this age group was similar to that in patients aged <80 years.
Trial registration number: ClinicalTrials.gov Registry (NCT03434015).
Keywords: Atrial Fibrillation; Epidemiology; Stroke.
© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: ET and PLC received unrestricted research grants from Boston Scientific and St Jude Medical for this study. PG is the medical director and shareholder of CERC (Cardiovascular European Research Center) and received speaker’s and advisory fees from Abbott and Boston Scientific. GR is proctor for Boston Scientific. RE is consultant and has performed proctoring for Boston Scientific and Abbott. None for all other authors.
